Background {#Sec1}
==========

Complex wounds are those that do not heal after a period of 3 months or more \[[@CR1]\]. These types of wounds are a significant burden on the healthcare system and result in patient and caregiver stress, economic loss, and decreased quality of life. At least 1% of individuals living in high economy countries will experience a complex wound in their lifetime \[[@CR2]\], and over 6.5 million individuals have a complex wound in the United States alone \[[@CR3]\]. Moreover, these types of wounds have a significant economic impact. For example, \$10 billion United States dollars (USD) per year in North America is spent managing complex wounds \[[@CR4]\], and 4% of the annual National Health Service expenditure in the United Kingdom is spent on care for patients with pressure ulcers \[[@CR5]\].

There are three main categories of complex wounds: i) wounds resulting from chronic disease (e.g., venous insufficiency, diabetes), ii) pressure ulcers, and iii) non-healing surgical wounds \[[@CR6]-[@CR8]\]. Treatment is targeted to the type of wound. Managing complex wounds resulting from disease usually involves improving the underlying disease; for example, optimizing diabetes control for patients with diabetes \[[@CR9]\]. A clinical assessment and history of mobility and neurological disability is often necessary to treat patients with pressure ulcers \[[@CR9]\]. Considerations for managing surgical wound infections include previous antibiotic treatment and immune response \[[@CR3]\].

It is estimated that the global wound care market will reach over \$22 billion USD annually by 2020 \[[@CR10]\]. Due to the burgeoning costs from the management of patients requiring complex wound care, policymakers are interested in finding cost-effective treatments. However, the cost-effectiveness of all interventions available to treat complex wounds is currently unclear. As such, we sought to elucidate cost-effective treatment strategies for complex wounds through a systematic review of cost-effectiveness analyses.

Methods {#Sec2}
=======

Protocol {#Sec3}
--------

The systematic review question was posed by members of the Toronto Central Local Health Integrated Network. In collaboration with the Toronto Central Local Health Integrated Network, our research team prepared a draft protocol that was revised to incorporate feedback from systematic review methodologists, policymakers, and clinicians with expertise in wound care (Additional file [1](#MOESM1){ref-type="media"}). Our protocol also included conducting a related project comprising an overview of systematic reviews for treating complex wounds, and these results are available in a separate publication \[[@CR11]\].

Information sources and search strategy {#Sec4}
---------------------------------------

On October 26, 2012, an experienced librarian conducted comprehensive literature searches in the following electronic databases from inception onwards: MEDLINE, EMBASE, and the Cochrane Library. The literature search was limited to adult patients and economic studies. The Peer Review of Electronic Search Strategies (PRESS) checklist \[[@CR12]\] was used by another expert librarian to peer review the literature search. The search was revised, as necessary, and the final MEDLINE search is presented in Additional file [2](#MOESM2){ref-type="media"}. Full literature searches for the other databases are available upon request. The reference lists of the included studies were searched to identify additional relevant studies.

Eligibility criteria {#Sec5}
--------------------

Inclusion criteria were defined using the 'Patients, interventions, comparators, outcomes, study designs, timeframe' (PICOST) framework \[[@CR13]\], as follows:

### Patients {#Sec6}

Adults aged 18 years and older experiencing complex wounds. Complex wounds included those due to chronic disease (such as diabetic foot ulcers or venous leg ulcers), pressure ulcers (such as decubitus ulcers or bed sores), and non-healing surgical wounds.

### Interventions {#Sec7}

All complex wound care interventions were included, as identified from our overview of systematic reviews \[[@CR11]\] and outlined in Additional file [3](#MOESM3){ref-type="media"}.

### Comparators {#Sec8}

All comparators were eligible for inclusion, including any of the eligible interventions in comparison with each other or versus no treatment or placebo or usual care.

### Outcomes {#Sec9}

Cost-effectiveness (i.e., both incremental cost and incremental effectiveness) was included, where effectiveness was measured by at least one of the following outcomes: quality-adjusted life-years (QALYs), wounds healed, ulcer-free/healing time, wound size reduction/improvement, or hospitalizations (number/length of stay).

### Study designs {#Sec10}

Economic evaluations were included in which the incremental cost-effectiveness ratios (ICERs) were reported or could be derived.

### Timeframe {#Sec11}

We did not limit inclusion to year of publication.

### Other limitations {#Sec12}

We limited cost-effectiveness analyses to those based on a study with a control group, and where the data were from direct comparisons (versus a review using indirect data). Both published and unpublished studies were eligible for inclusion. Although we focused inclusion on those studies written in English, we contacted the authors of potentially relevant non-English studies to obtain the English translation.

Screening process for study selection {#Sec13}
-------------------------------------

The team pilot-tested the pre-defined eligibility criteria using a random sample of 50 included titles and abstracts. After 90% agreement was reached, each title and abstract was screened by two team members, independently, using our Synthesi.SR tool \[[@CR14]\]. Discrepancies were resolved by discussion or the involvement of a third reviewer. The same process was followed for screening full-text articles that were identified as being potentially relevant after screening their titles and abstracts.

Data abstraction and data collection process {#Sec14}
--------------------------------------------

The team pilot-tested data abstraction forms using a random sample of five included cost-effectiveness analyses. Subsequently, two investigators independently read each article and abstracted relevant data. Differences in abstraction were resolved by discussion or the involvement of a third reviewer. Data items included study characteristics (e.g., type of economic evaluation, time horizon, treatment interventions examined, study comparators), patient characteristics (e.g., clinical population, wound type), and cost-effectiveness results (e.g., ICERs, cost per QALY, cost per wound healed). The perspective of the economic evaluation was categorized as: patient, public payer, provider, healthcare system, or society \[[@CR15]\].

Cost-effectiveness studies can have four possible overall results, which are often represented graphically in quadrants on a cost-effectiveness plane \[[@CR16]\]. The possibilities for the intervention versus a comparator are: 1) more effective and less costly, which we noted as 'dominant'; 2) more effective and more costly; 3) less effective and less costly; and 4) less effective and more costly, which we noted as 'dominated'. The first possibility is considered to be cost-effective; whereas possibility 4 is not cost-effective. Situations 2 and 3 requires judgment by the decision-maker to interpret \[[@CR17]\], and in such cases, the decision is often dependent on the decision-maker's willingness to pay. For interventions that were found to be more effective yet more costly (i.e., situation 2) or less effective and less costly (situation 3), ICERs were reported or derived from both the differences in cost (i.e., incremental cost) and effectiveness (i.e., incremental effectiveness) between the study's intervention and comparator groups using the formula:

(Cost of the intervention -- Cost of the comparator) ÷ (Effectiveness of the intervention -- Effectiveness of the comparator)

To assess key variables influencing the cost-effectiveness results, sensitivity analyses, level of uncertainty in the cost and benefit estimates, and incremental variabilities (i.e., the variability of the incremental cost and the variability of the incremental effectiveness), were reported.

Authors of the included cost-effectiveness analyses were contacted for data verification, as necessary. Further, multiple studies reporting the same economic data were sorted into the major publication (e.g., most recent paper or largest sample size) and companion report. Our results focus on the major publications and the companion reports were used to provide supplementary material.

Methodological quality appraisal {#Sec15}
--------------------------------

The methodological quality of the cost-effectiveness analyses was appraised using a 10-item tool developed by Drummond et al. (Additional file [4](#MOESM4){ref-type="media"}) \[[@CR18]\]. The items on this tool include the appraisal of question definition, description of competing alternatives, effectiveness of the intervention, consideration of all relevant costs, measurement of costs, valuation of costs and consequences, cost adjustment/discounting, incremental analysis, uncertainty/sensitivity analysis, and discussion of study results. The Drummond score can range from 0 to 10. Each included cost-effectiveness analysis was appraised by two team members and conflicts were resolved by discussion or the involvement of a third reviewer.

Synthesis {#Sec16}
---------

Since the purpose of this systematic review was to summarize the cost-effectiveness of interventions for complex wound care, the results are reported descriptively. The costing data from all studies were converted to 2013 USD to increase the comparability of the economic results across cost-effectiveness studies. This process entailed first converting the currencies into USD using purchasing power parities for the particular year of the data \[[@CR19],[@CR20]\], and then adjusting these for inflation to the year 2013 (rounded to the nearest dollar) using the consumer price index for medical care in the United States \[[@CR21]\].

Results {#Sec17}
=======

Literature search and screening {#Sec18}
-------------------------------

The literature search identified 422 potentially relevant full-text articles after screening 6,200 titles and abstracts (Figure [1](#Fig1){ref-type="fig"}). There were 59 included cost-effectiveness analyses that fulfilled our eligibility criteria and were included \[[@CR22]-[@CR80]\], plus an additional three companion reports \[[@CR81]-[@CR83]\].Figure 1**Study flow diagram.**

Study and patient characteristics {#Sec19}
---------------------------------

The cost-effectiveness analyses evaluated interventions to treat venous ulcers (41%), diabetic ulcers (27%), and pressure ulcers (24%) (Table [1](#Tab1){ref-type="table"}). The studies were published between 1988 and 2012. Most of the papers were conducted in the United Kingdom (29%) and United States (27%). Almost half (49%) reported private or mixed (private and public) funding sources of the studies, while one-third (34%) did not report a source of funding.Table 1**Summary characteristics of all cost-effectiveness analyses (CEAs)CharacteristicNo. of CEAs (n = 59)Percentage of CEAsOriginal year of values**  1982--19961525.4  1997--20001932.2  2001--20051016.9  2006--20101525.4**Year of publication**  1988--1996711.9  1997--20012135.6  2002--20061220.3  2007--20121932.2**Country of conduct**  Europe (17 from the UK)3457.6  North America (16 from USA)1932.2  Asia35.1  Australia and New Zealand35.1**Perspective**  Public payer1728.8  Society813.6  Provider610.2  Health care system11.7  Not reported2745.8**Efficacy study design**  RCT4474.6  Observational915.3  Systematic review of RCT46.8  Systematic review^a^11.7  Pseudo-RCT11.7**Sample size** ^**b**^  10--3046.8  31--501118.6  51--1001220.3  101--15058.5  151--20035.1  201--4001627.1  \>400813.6**Patient age** ^**c**^ **(years)**  50--5958.5  60--692033.9  70--791830.5  80--89813.6  Not reported813.6**Timeframe**  ≤12 weeks2847.5  13--24 weeks915.3  \>24 weeks2237.3**Funding source** ^**d**^  Private2339.0  Public1016.9  Mixed610.2  Not reported2033.9**Type of wound**  Venous ulcers2440.7  Diabetic ulcers1627.1  Pressure ulcers1423.7  Mixed wounds35.1  Mixed venous and venous/arterial ulcers23.4**Unit of effectiveness**  Additional wound healed2644.1  QALY gained1016.9  Ulcer-free time (day/week/month) gained915.3  Percentage additional reduction of ulcer (area/volume/volume per week)813.6  Increase in healing rate23.4  Reduction in DESIGN score11.7  Patient-year gained11.7  Hospital-free day gained11.7  Foot-related hospitalization avoided11.7**Interventions** ^**e**^  Dressings1724.3  Bandage1217.1  Biologics811.4  Topical Tx811.4  Wound care programs710.0  Devices57.1  Skin replacement Tx45.7  Oral Tx34.3  Support surfaces22.9  Stockings11.4  Surgery11.4  Wound cleansing11.4  Unspecified11.4**Comparators** ^**e**^  Dressings1724.3  Bandage811.4  No Tx68.6  Biologics45.7  Stockings22.9  Support surfaces22.9  Topical Tx22.9  Wound care programs22.9  Devices11.4  Surgery11.4  Usual care/Unspecified2535.7QALY, Quality-adjusted life-year; RCT, Randomized clinical trial; Tx, Therapy/treatment.^**a**^Not specified if the included studies were RCTs.^**b**^For studies based on a review, this refers to the total sample size of the combined studies that the data were estimated from.^**c**^Age here refers to mean age or the age used in the model.^**d**^Mixed here indicates both private and public funding.^**e**^Numbers do not add up to 59 as some studies contributed data to more than one category.

While the majority of studies based effectiveness on a (single) randomized clinical trial (75%), only a few based effectiveness on a systematic review (9%) and 15% were based on observational studies (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). Almost half (46%) of the economic studies included a sample size of 10 to 100 patients and the rest had a sample of \>100 patients. In addition, 48% were conducted in a timeframe of 12 weeks or less, while the other studies had a duration of \>12 weeks follow-up. Across the 59 economic studies, 9 different units of effectiveness were used, with the most common ones being healed wound (44%) and QALY (17%). Regarding the perspective of the cost-effectiveness analysis, almost half (46%) did not report this explicitly and 29% reported using the public payer perspective.Table 2**Characteristics of each cost-effectiveness analysis (CEA) for venous ulcers (n = 24)CEA (Original year of values)Country (Original currency)PerspectiveEfficacy study designSample sizePopulationTimeframeFunding source** ^**a**^Augustin 1999 (1989) \[[@CR22]\]Germany (DM)Not reportedRCT25Mean 61 yrs; venous insufficiency24 wksNot reportedDePalma 1999 (1998) \[[@CR23]\]USA (US\$)Not reportedRCT38Mean 61 yrs; venous insufficiencymax. 12 wksPrivateGlinski 1999 (1998) \[[@CR24]\]Poland (PLN)Public payerRCT140Mean 65 yrs; venous insufficiency24 wksNot reportedGordon 2006 (2005) \[[@CR25]\]Australia (AU\$)SocietyRCT56Most \>71 yrs; venous insufficiency24 wksNot reportedGuest 2012 (2010) \[[@CR26]\]UK (£)Public payerObservational510Mean 80 yrs; venous insufficiency24 wksPrivateIglesias 2006 (2004) \[[@CR27]\]UK (£)Public payerSR of RCTs43466 yrs; venous insufficiency52 wksPublicIglesias 2004 (2001) \[[@CR28]\]UK (£)Public payerRCT387Mean 71 yrs; venous insufficiency52 wksPublicJull 2008 (2005) \[[@CR29]\]New Zealand (NZ\$)Public payerRCT368Mean 68 yrs; venous insufficiency12 wksMixedJunger 2008 (2007) \[[@CR30]\]Germany (DM)Not reportedRCT39Mean 67 yrs; venous insufficiency17 wksPrivateKerstein 2000 (1995) \[[@CR31]\]USA (US\$)Not reportedObservational81Mean 65 yrs; venous insufficiency3 yrsNot reportedKikta 1988 (1987) \[[@CR32]\]USA (US\$)Not reportedRCT87Venous insufficiency; (ages NR)24 wksNot reportedMichaels 2009 (2007) \[[@CR33]\]UK(£)Public payerRCT213Mean 71 yrs; venous insufficiency12 wksPublicMorrell 1998 (1995) \[[@CR34]\]UK (£)Public payerRCT233Mean 74 yrs; venous insufficiency52 wksPublicO'Brien 2003 (2000) \[[@CR35]\]Ireland (€)Public payerRCT200Mean 72 yrs; venous insufficiency12 wksPrivateOien 2001 (1997) \[[@CR36]\]Sweden (£)Not reportedObservational68Mean 76 yrs; venous insufficiency12 wksNot reportedSibbald 2001 (1997) \[[@CR37]\]Canada (CAN\$)SocietyRCT293Elderly; venous insufficiency13 wksPrivateTaylor 1998 (1987) \[[@CR38]\]UK (£)Not reportedRCT36Mean 75 yrs; venous insufficiency12 wksPrivateUkat 2003 (2002) \[[@CR39]\]Germany (€)Not reportedRCT89Mean 69 yrs; venous insufficiency12 wksPrivateWatson 2011 (2007) \[[@CR40]\]UK (£)Public payerRCT337Mean 69 yrs; venous insufficiency52 wksPublicPham 2012 (2009) \[[@CR41]\]Canada (CAN\$)SocietyRCT424Mean 65 yrs; venous insufficiency; most fully mobilemax. 52 wksPublicSchonfeld 2000 (1996) \[[@CR42]\]USA(US\$)Public payerRCT240Mean 60 yrs; venous insufficiency52 wksPrivateSimon 1996 (1993) \[[@CR43]\]UK (£)Not reportedObservational901Venous insufficiency; (ages not reported)13 wksMixedCarr 1999 (1998) \[[@CR44]\]UK (£)Public payerRCT233Mean 73 yrs; venous insufficiency52 wksPrivateGuest 2009 (2007) \[[@CR45]\]UK (£)Public payerRCT83Mean 71 yrs; venous insufficiency52 wksPrivateRCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.^**a**^Mixed here indicates both private and public funding.Table 3**Characteristics of each cost-effectiveness analysis (CEA) for venous and venous/arterial ulcers (n = 2)CEA (Original year of values)Country (Original currency)PerspectiveEfficacy study designSample sizePopulationTimeframeFunding source**Dumville 2009 (2006) \[[@CR46]\]UK (£)Public payerRCT267Mean 74 yrs; venous insufficiency52 wksNot reportedOhlsson 1994 (1993) \[[@CR47]\]Sweden (SEK)Not reportedRCT30Median 76 yrs; venous insufficiency; most female6 wksNot reportedRCT, Randomized clinical trial; WKS, Weeks; Yrs, Years.Table 4**Characteristics of each cost-effectiveness analysis (CEA) for diabetic ulcers (n = 16)CEA (Original year of values)Country (Original currency)PerspectiveEfficacy study designSample sizePopulationTimeframeFunding source** ^**a**^Abidia 2003 (2000) \[[@CR48]\]UK (£)Not reportedRCT18Mean 71 yrs; diabetes52 wksNot reportedApelqvist 1996 (1993) \[[@CR49]\]Sweden (SEK)SocietyRCT41Included \>40 yrs; diabetes12 wksMixedEdmonds 1999 (1996) \[[@CR50]\]UK (£)ProviderRCT40Mean 66 yrs; diabetes; foot infections2 wksPrivateGuo 2003 (2001) \[[@CR51]\]USA (US\$)SocietySR^b^12660 yrs; diabetes12 yrsNot reportedHabacher 2007 (2001) \[[@CR52]\]Austria (€)SocietyObservational119Mean 65 yrs; diabetes15 yrsNot reportedHorswell 2003 (1999) \[[@CR53]\]USA (US\$)Not reportedObservational214Mean 54 yrs; diabetes; mostly African-Americans52 wksNot reportedJansen 2009 (2006) \[[@CR54]\]UK (£)Public payerRCT402Mean 58 yrs; diabetesapprox. 4 wksPrivateJeffcoate 2009 (2007) \[[@CR55]\]UK (£)Public payerRCT317Mean 60 yrs; diabetes24 wksPublicMcKinnon 1997 (1994) \[[@CR56]\]USA (US\$)ProviderRCT90Mean 60 yrs; diabetes; limb-threatening foot infections3 wksPrivatePersson 2000 (1999) \[[@CR57]\]Sweden (US\$)Not reportedSR of RCTs500Median 60 yrs; diabetes52 wksPrivatePiaggesi 2007 (2006) \[[@CR58]\]Italy (€)Not reportedRCT40Mean 60 yrs; diabetes12 wksPrivateRedekop 2003 (1999) \[[@CR59]\]The Nether-lands (€)SocietyRCT208Elderly; diabetes52 wksPrivateAllenet 2000 (1998) \[[@CR60]\]France (FF)SocietyRCT235Diabetes; (ages not reported)52 wksNot reportedGhatnekar 2002 (2000) \[[@CR61]\]France (€)Not reportedRCT157Diabetes; (ages not reported)52 wksPrivateGhatnekar 2001 (1999) \[[@CR62]\]UK(US\$)Public payerSR of RCTs449Diabetes; (ages not reported)52 wksPrivateHailey 2007 (2004) \[[@CR63]\]Canada (CAN\$)Public payerSR of RCTs30565 yrs; diabetes12 yrsPublicRCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.^**a**^Mixed here indicates both private and public funding.^**b**^Not specified if the included studies were RCTs or not (but states they were prospective controlled clinical studies).Table 5**Characteristics of each cost-effectiveness analysis (CEA) for pressure ulcers (n = 14)CEA (Original year of values)Country (Original currency)PerspectiveEfficacy study designSample sizePopulationTimeframeFunding source** ^**a**^Branom 2001 (2000) \[[@CR64]\]USA (US\$)Not reportedRCT20Mean 72 yrs; bedriddenmax. 8 wksNot reportedBurgos 2000 (1998) \[[@CR65]\]Spain (Pta)Not reportedRCT37Mean 80 yrs12 wksPrivateChang 1998 (1997) \[[@CR66]\]Malaysia (RM)Not reportedRCT34Mean 58 yrsmax. 8 wksPrivateChuangsu-wanich 2011 (2010) \[[@CR67]\]Thailand (US\$)Not reportedRCT45Mean 66 yrs8 wksNot reportedFerrell 1995 (1992) \[[@CR68]\]USA (US\$)ProviderRCT84Mean 81 yrs; mostly Caucasians; most fecal incontinence52 wksMixedFoglia 2012 (2010) \[[@CR69]\]Italy (€)ProviderObservational362Most \>80 yrs4.3 wksNot reportedGraumlich 2003 (2001) \[[@CR70]\]USA (US\$)Not reportedRCT65Mean 83 yrs8 wksPublicMuller 2001 (1998) \[[@CR71]\]The Netherlands (NLG)ProviderRCT24Mean 73 yrs; all females12 wksPrivateNarayanan 2005 (2004) \[[@CR72]\]USA (US\$)Not reportedObservational976Most ≥80 yrs; mostly Caucasiansapprox. 22 wksPayne 2009 (2007) \[[@CR73]\]USA (US\$)ProviderRCT36Mean 73 yrs4 wksPrivateRobson 2000 (1999) \[[@CR74]\]USA (US\$)Not reportedRCT61Mean 50 yrs; mostly Caucasians5 wksMixedSanada 2010 (2007) \[[@CR75]\]Japan (Yen)Not reportedObservational105Mean 75 yrs3 wksNot reportedXakellis 1992 (1990) \[[@CR76]\]USA (US\$)Not reportedRCT39Mean 80 yrs1.4 wksMixedSeberrn 1986 (1985) \[[@CR77]\]USA (US\$)Not reportedRCT77Mean 74 yrs8 wksNot reportedRCT, Randomized clinical trial; SR, Systematic review; wks, Weeks; yrs, Years.^**a**^Mixed here indicates both private and public funding.Table 6**Characteristics of each cost-effectiveness analysis (CEA) for mixed wound types (n = 3)CEA (Original year of values)Country (Original currency)PerspectiveEfficacy study designSample sizePopulationTimeframeFunding source**Bale 1998 (1994) \[[@CR78]\]UK (£)Not reportedRCT100Mean 76 yrsmax. 8 wksPrivateTerry 2009 (2008) \[[@CR79]\]USA (US\$)Not reportedRCT160Mean 58 yrs6 wksPublicVu 2007 (2000) \[[@CR80]\]Australia (AU\$)Health care systemPseudo-RCT342Mean 83 yrs20 wksPublicRCT, Randomized clinical trial; wks, Weeks; Yrs, Year.

Methodological quality appraisal {#Sec20}
--------------------------------

Approximately 71% (42 out of 59) of the cost-effectiveness analyses had a score of 8 or higher out of a total possible score of 10 (Additional file [5](#MOESM5){ref-type="media"}, Figure [2](#Fig2){ref-type="fig"}). Using the Drummond 10-item tool \[[@CR18]\], the key methodological shortcoming across the cost-effectiveness analyses was that only 51% (30 out of 59) had established the 'effectiveness' of the intervention using data from efficacy studies (i.e., systematic reviews, randomized clinical trials or observational studies) that had sufficiently large sample sizes according to the International Conference on Harmonisation guidelines for establishing efficacy \[[@CR84]\]. Consistent methodological strengths across the cost-effectiveness analyses included a clear research question, costs and consequences measured in appropriate physical units, credibly valued costs and consequences, and discounted costs (when applicable).Figure 2**Drummond methodological quality summary results (n = 59).** Items: **1.** Well-defined question. **2.** Competing alternatives well described. **3.** Effectiveness established. **4.** All important and relevant costs and consequences identified. **5.** Measurement accurately performed. **6.** Valuation credibility. **7.** Discounting. **8.** Incremental analysis performed. **9.** Allowance made for uncertainty. **10.** Discussion.

Cost-effectiveness results {#Sec21}
--------------------------

Due to the large number of cost-effectiveness studies included and the numerous results, we have focused on dominant results in the text. However, all of the cost-effectiveness results are presented in Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"} and [11](#Tab11){ref-type="table"} and the sensitivity analyses, level of uncertainty, and incremental variabilities are outlined in Additional file [6](#MOESM6){ref-type="media"}.Table 7**Cost-effectiveness analysis (CEA) outcomes for venous ulcers (n = 24)CEA (Original year of values)Treatment vs. ComparatorICER summary/estimate \[2013 US\$\]Unit of effectivenessIncremental cost \[2013 US\$\]Incremental effectiveness**Augustin 1999 (1989) \[[@CR22]\]Hydrocolloid dressing vs. Vaseline gauze dressingDominantUlcer-free week gained−3,3621.3DePalma 1999 (1998) \[[@CR23]\]Thera-boot vs. Unna's bootDominantUlcer-free week gained−6011.71Glinski 1999 (1998) \[[@CR24]\]Micronized purified flavonoid fraction + SC vs. SC aloneDominant^a^Additional wound healed−7140.19Gordon 2006 (2005) \[[@CR25]\]Community leg club vs. community home nursing488^a^Additional wound healedNot reportedNot reportedGuest 2012^b^ (2010) \[[@CR26]\]NSBF vs. DBC18^a^Percent additional reduction of ulcer area1468Guest 2012^b^ (2010) \[[@CR26]\]NSBF vs. no skin protectant1^a^Percent additional reduction of ulcer area1722Guest 2012^b^ (2010) \[[@CR26]\]DBC vs. no skin protectantDominant^a^Percent additional reduction of ulcer area−12914Iglesias 2006 (2004) \[[@CR27]\]Pentoxifylline plus compression vs. placebo plus compressionDominant^a^QALY gained−2130.01Iglesias 2004 (2001) \[[@CR28]\]Four-layer bandage vs. short-stretch bandageDominant^a^QALY gained−5660.02Jull 2008 (2005) \[[@CR29]\]Manuka honey dressing vs. UCDominant^a,c^Additional wound healed−480.06Junger 2008 (2007) \[[@CR30]\]Low-frequency pulsed current (Dermapulse) vs. placeboMore costly & more effective^d^Percent additional reduction of ulcer areaNot reportedNot reportedKerstein 2000^b^ (1995) \[[@CR31]\]Hydrocolloid dressing plus compression hosiery vs. Unna's bootDominantAdditional wound healed−6,7480.18Kerstein 2000^b^ (1995) \[[@CR31]\]Unna's boot vs. saline gauze plus compression hosieryMore costly & more effective^d^Additional wound healedNot reportedNot reportedKikta 1988 (1987) \[[@CR32]\]Unna's boot vs. hydrocolloid (DuoDERM)Dominant^a^Additional wound healed−2090.32Michaels 2009 (2007) \[[@CR33]\]Antimicrobial silver-donating dressings vs. low-adherent dressings917,298^a^QALY gained1830.0002Morrell 1998 (1995) \[[@CR34]\]Community leg ulcer clinics using four-layer compression bandaging vs. home nursing UC7^a^Ulcer-free week gained445.9O'Brien 2003 (2000) \[[@CR35]\]Four-layer bandage vs. UCDominant^a^Increase in healing rate−420.2Oien 2001 (1997) \[[@CR36]\]Pinch grafting in primary care vs. pinch grafting in hospitalCost saving & same effectivenessAdditional wound healed−14,0750Sibbald 2001 (1997) \[[@CR37]\]Skin substitute (Apligraf) plus four-layer bandage vs. four-layer bandage only6095^a^Additional wound healed4570.075Taylor 1998 (1987) \[[@CR38]\]Four-layer high-compression bandaging vs. UCDominant^a^Additional wound healed−6590.095Ukat 2003 (2002) \[[@CR39]\]Multilayer elastic bandaging (Profore) vs. short-stretch bandagingDominant^a^Additional wound healed−1,1980.08Watson 2011 (2007) \[[@CR40]\]Ultrasound plus SC vs. SC aloneDominated^a^QALY gained371−0.009Pham 2012 (2009) \[[@CR41]\]Four-layer bandaging vs. short-stretch bandaging43,918^a^QALY gained3950.009Schonfeld 2000 (1996) \[[@CR42]\]Apligraf (Graftskin) vs. Unna's BootDominant^a^Ulcer-free month gained−13,8832.85Simon 1996 (1993) \[[@CR43]\]Community leg ulcer clinic vs. UC clinicDominantAdditional wound healed−1,8260.22Carr 1999 (1998) \[[@CR44]\]Four-layer compression bandaging (Profore) vs. UCDominant^a^Additional wound healed−1,2890.13Guest 2009 (2007) \[[@CR45]\]Amelogenin plus compression therapy vs. compression therapy onlyDominant^a^QALY gained−8350.054DBC, Durable barrier cream; ICER, Incremental cost-effectiveness ratio; NSBF, No sting barrier film; QALY, Quality-adjusted life-year; SC, Standard care; UC, Usual care; US\$, United States dollars.^**a**^Denotes the higher quality studies (Drummond score ≥8).^**b**^Multiple comparisons are reported.^**c**^ICER was mostly due to an extra 3 patients hospitalized in control group... "probably due to random variation". If remove these costs, the dominance is reversed in favor of UC.^**d**^Unable to calculate specific ICER for these 2 studies because the data was not reported for all treatment arms or presented in a figure only but the overall result (more costly & more effective) was reported.Table 8**Cost-effectiveness analysis (CEA) outcomes for venous and venous/arterial ulcers (n = 2)CEA (Original year of values)Treatment vs. ComparatorICER summary/estimate \[2013 US\$\]Unit of effectivenessIncremental cost \[2013 US\$\]Incremental effectiveness**Dumville 2009 (2006) \[[@CR46]\]larval therapy vs. hydrogel17,757^a^QALY gained1950.011Ohlsson 1994 (1993) \[[@CR47]\]hydrocolloid (DuoDERM) dressing vs. saline gauzeDominant^a^Additional wound healed−5880.357ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year; US\$, United States dollars.^**a**^Denotes the higher quality studies (Drummond score ≥8).Table 9**Cost-effectiveness analysis (CEA) outcomes for diabetic ulcers (n = 16)CEA (Original year of values)Treatment vs. ComparatorICER summary/estimate \[2013 US\$\]Unit of effectivenessIncremental cost \[2013 US\$\]Incremental effectiveness**Abidia 2003 (2000) \[[@CR48]\]HBOT vs. controlDominantAdditional wound healed−7,5960.625Apelqvist 1996 (1993) \[[@CR49]\]Cadexomer iodine ointment vs. standard treatmentDominant^a^Additional wound healed−1190.183Edmonds 1999 (1996) \[[@CR50]\]Filgrastim vs. placeboDominant^a,b^Hospital-free day gained−7,7387.5Guo 2003 (2001) \[[@CR51]\]HBOT + SC vs. SC alone3508^a^QALY gained2,1370.609Habacher 2007 (2001) \[[@CR52]\]Intensified treatment vs. SCDominant^a^Patient-year gained−7,6252.97Horswell 2003 (1999) \[[@CR53]\]Staged management diabetes foot program vs. SCDominant^a^Foot-related hospitalization avoided−7,8480.41Jansen 2009 (2006) \[[@CR54]\]Ertapenem vs. Piperacillin/TazobactamDominant^a^Lifetime QALY gained−8220.12Jeffcoate 2009^c^ (2007) \[[@CR55]\]Hydrocolloid (Aquacel) vs. antiseptic (Inadine)1449^a^Additional wound healed140.01Jeffcoate 2009^c^ (2007) \[[@CR55]\]Antiseptic (Inadine) vs. non-adherent dressing1590^a^Additional wound healed800.05McKinnon 1997 (1994) \[[@CR56]\]Ampicillin/sulbactam vs. imipenem/cilastatinDominant^a^Hospitalization day avoided−5,8913.5Persson 2000 (1999) \[[@CR57]\]Becaplermin plus GWC (unspecified) vs. GWC aloneDominant^a^Ulcer-free month gained−6280.81Piaggesi 2007 (2006) \[[@CR58]\]Total contact casting vs. Optima Diab device8,578Additional wound healed8580.1Redekop 2003 (1999) \[[@CR59]\]Apligraf (skin substitute) + GWC^d^ vs. GWC aloneDominant^a^Ulcer-free month gained−1,2231.53Allenet 2000 (1998) \[[@CR60]\]Dermagraft (human dermal replacement) vs. SC70,961^a^Additional wound healed12,6520.178Ghatnekar 2002 (2000) \[[@CR61]\]Promogran dressing plus GWC^e^ vs. GWC aloneDominant^a^Additional wound healed−2940.042Ghatnekar 2001 (1999) \[[@CR62]\]Becaplermin gel (containing recombinant human platelet-derived growth factor) plus GWC^f^ vs. GWC aloneDominant^a^Ulcer-free month gained−7940.81Hailey 2007 (2004) \[[@CR63]\]HBOT + SC vs. SC aloneDominantQALY gained−9,3370.63GWC, Good wound care; HBOT, Hyperbaric oxygen therapy; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year; SC, Standard care; US\$, United States dollars.^**a**^Denotes the higher quality studies (Drummond score ≥8).^**b**^"Patient selection may have occurred during the in-hospital stay where more control patients experienced a bad vascular condition requiring the more costly interventions".^**c**^Multiple comparisons are reported.^**d**^GWC, "the best wound care available and consists mainly of offloading, debridement, and moist dressings".^**e**^GWC, "sharp debridement (if necessary) and wound cleansing. In the GWC alone arm, the primary dressing was saline-soaked gauze and the secondary gauze and tape".^**f**^GWC, "sharp debridement to remove callus, fibrin and necrotic tissue; moist saline dressing changes every 12 hours; systematic control of infection, if present; glucose control; and offloading of pressure".Table 10**Cost-effectiveness analysis (CEA) outcomes for pressure ulcers (n = 14)CEA (Original year of values)Treatment vs. ComparatorICER summary/estimate \[2013 US\$\]Unit of effectivenessIncremental cost \[2013 US\$\]Incremental effectiveness**Branom 2001 (2000) \[[@CR64]\]Constant Force Technology mattress vs. low-air-loss mattressDominantPercent additional reduction in wound volume per week−1,4350.04Burgos 2000 (1998) \[[@CR65]\]Collagenase ointment vs. hydrocolloid (Varihesive) dressing1,278Percent additional reduction of ulcer area20,82516.3Chang 1998 (1997) \[[@CR66]\]Hydrocolloid (DuoDERM CGF) vs. saline gauze3Percent additional reduction of ulcer area12143Chuangsu-wanich 2011 (2010) \[[@CR67]\]Silver mesh dressing vs. silver sulfadiazine creamDominantIncrease in healing rate−1,69511.89Ferrell 1995 (1992) \[[@CR68]\]Low-air-loss bed vs. conventional foam mattress58^a^Ulcer-free day gainedNot reportedNot reportedFoglia 2012 (2010) \[[@CR69]\]Advanced dressings vs. simple dressingsDominant^a^Percent additional reduction of ulcer area−1326Graumlich 2003 (2001) \[[@CR70]\]Collagen (Medifil) vs. hydrocolloid (DuoDERM)63,147^a^Additional wound healed6320.01Muller 2001 (1998) \[[@CR71]\]Collagenase-containing ointment (Novuxol) vs. hydrocolloid (DuoDERM) dressingDominant^a^Additional wound healed−1490.281Narayanan 2005^b^ (2004) \[[@CR72]\]Initial wound stage 1: BCT (balsam Peru + hydrogenated castor oil + trypsin ointment) only vs. BCT + Others (BCT plus Other treatments)DominantAdditional wound healed−50.106Narayanan 2005^b^ (2004) \[[@CR72]\]Initial wound stage 1: BCT + Others vs. OthersDominantAdditional wound healed−100.263Narayanan 2005^b^ (2004) \[[@CR72]\]Initial wound stage 2: BCT only vs. OthersDominantAdditional wound healed−60.16Narayanan 2005^b^ (2004) \[[@CR72]\]Initial wound stage 2: BCT only vs. BCT + OthersDominantAdditional wound healed−70.159Narayanan 2005^b^ (2004) \[[@CR72]\]Initial wound stage 2: BCT + Others vs. Others226,208Additional wound healed2260.001Payne 2009 (2007) \[[@CR73]\]Polyurethane foam dressing (Allevyn Thin) vs. saline gauzeDominantAdditional wound healed−5640.181Robson 2000^b^ (1999) \[[@CR74]\]Sequential GM-CSF and bFGF vs. bFGF onlyDominantPercent additional reduction of ulcer volume1,357−0.07Robson 2000^b^ (1999) \[[@CR74]\]Sequential GM-CSF and bFGF vs. GM-CSF onlyDominantPercent additional reduction of ulcer volume−8481Robson 2000^b^ (1999) \[[@CR74]\]Placebo vs. sequential GM-CSF and bFGF735Percent additional reduction of ulcer volume2,2053Sanada 2010 (2007) \[[@CR75]\]New incentive system vs. non-introduced controlDominantreduction in DESIGN score−164.1Xakellis 1992 (1990) \[[@CR76]\]Hydrocolloid (DuoDERM) vs. gauzeDominant^a^ulcer-free day gained−252Sebern 1986^b^ (1985) \[[@CR77]\]Grade II PrU: MVP vs. gauzeDominant^a^percent additional reduction of ulcer area−1,92548Sebern 1986^b^ (1985) \[[@CR77]\]Grade III PrU: MVP vs. gauze9^a^percent additional reduction of ulcer area21723BCT, Balsam Peru plus hydrogenated castor oil plus trypsin ointment; bFGF, Basic fibroblast growth factor; GM-CSF, Granulocyte-macrophage/colony-stimulating factor; ICER, Incremental cost-effectiveness ratio; MVP, Moisture vapor permeable dressing; PrU, Pressure ulcer; QALY, Quality-adjusted life-year; US\$, United States dollars.^**a**^Denotes the higher quality studies (Drummond score ≥8).^**b**^Multiple comparisons are reported.Table 11**Cost-effectiveness analysis (CEA) outcomes for mixed wound types (n = 3)CEA (Original year of values)Treatment vs. ComparatorICER summary/estimate \[2013 US\$\]Unit of effectivenessIncremental cost \[2013 US\$\]Incremental effectiveness**Bale 1998 (1994) \[[@CR78]\]Hydrocellular (Allevyn) dressing vs. hydrocolloid (Granuflex) dressing26Additional wound healed30.13Terry 2009 (2008) \[[@CR79]\]Telemedicine plus WCS consults vs. WCS consults onlyDominated^a^Additional wound healed2,085−0.249Vu 2007 (2000) \[[@CR80]\]Multidisciplinary wound care team vs. UCDominant^b^Additional wound healed−3460.092ICER, Incremental cost-effectiveness ratio; UC, Usual care; US\$, United States dollars; WCS, Wound care specialist.^**a**^"Disproportionate distribution, by chance, in group A \[telemedicine plus WCS consults\] of large non-healing surgical wounds and large, numerous pressure ulcers".^**b**^Denotes the higher quality study (Drummond score ≥8).

### Venous ulcers {#Sec22}

Twenty-four cost-effectiveness analyses examined interventions for venous ulcers (Table [7](#Tab7){ref-type="table"}) \[[@CR22]-[@CR45],[@CR83]\]. Sixteen studies found the interventions were dominant (i.e., more effective and less costly) \[[@CR22]-[@CR24],[@CR26]-[@CR29],[@CR31],[@CR32],[@CR35],[@CR38],[@CR42]-[@CR45]\], and 12 of these were studies with a Drummond score ≥8 \[[@CR24],[@CR26]-[@CR29],[@CR32],[@CR35],[@CR38],[@CR39],[@CR42],[@CR44],[@CR45]\]. These included Apligraf (Graftskin) vs. Unna's Boot \[[@CR42]\], Unna's boot vs. hydrocolloid (DuoDERM) \[[@CR32]\], micronized purified flavonoid fraction plus usual care vs. usual care alone \[[@CR24]\], durable barrier cream vs. no skin protectant \[[@CR26]\], pentoxifylline plus compression vs. placebo plus compression \[[@CR27]\], Manuka honey dressing vs. usual care \[[@CR29]\], amelogenin plus compression therapy vs. compression therapy only \[[@CR45]\], and four-layer compression bandaging vs. usual care \[[@CR35],[@CR38],[@CR44]\]. Although four-layer compression bandaging vs. short-stretch compression bandaging was found to be dominant in two studies \[[@CR28],[@CR39]\]\], this intervention was more effective and more costly in another economic evaluation \[[@CR41]\].

Dominant interventions from four studies scoring \<8 on the Drummond tool \[[@CR22],[@CR23],[@CR31],[@CR43]\] included hydrocolloid dressing vs. Vaseline gauze dressing \[[@CR22]\], hydrocolloid dressing plus compression hosiery vs. Unna's boot \[[@CR31]\], Thera-boot vs. Unna's boot \[[@CR23]\], and community leg ulcer clinic vs. usual care clinic \[[@CR43]\].

### Mixed venous and venous/arterial ulcers {#Sec23}

Two cost-effectiveness analyses evaluated interventions for mixed venous and venous/arterial ulcers (Table [8](#Tab8){ref-type="table"}) \[[@CR46],[@CR47]\]. Only one study found an intervention to be dominant (and had a Drummond score ≥8); hydrocolloid (DuoDERM) dressing was dominant compared to saline gauze \[[@CR47]\].

### Diabetic ulcers {#Sec24}

Sixteen cost-effectiveness analyses examined interventions for diabetic ulcers (Table [9](#Tab9){ref-type="table"}) \[[@CR48]-[@CR63]\]. Twelve studies found the interventions were dominant \[[@CR48]-[@CR50],[@CR52]-[@CR54],[@CR56],[@CR57],[@CR59],[@CR61]-[@CR63]\], and 10 of these were studies with a Drummond score ≥8 \[[@CR49],[@CR50],[@CR52]-[@CR54],[@CR56],[@CR57],[@CR59],[@CR61],[@CR62]\]. These included becaplermin gel (containing recombinant human platelet-derived growth factor) plus good wound care (GWC) vs. GWC alone (note: the various GWC definitions used are outlined in Table [9](#Tab9){ref-type="table"}) \[[@CR57],[@CR62]\], cadexomer iodine ointment vs. usual care \[[@CR49]\], filgrastim vs. placebo \[[@CR50]\], intensified treatment vs. usual care \[[@CR52]\], staged management diabetes foot program vs. usual care \[[@CR53]\], ertapenem vs. piperacillin/tazobactam \[[@CR54]\], ampicillin/sulbactam vs. imipenem/cilastatin \[[@CR56]\], Apligraf (skin substitute) plus GWC vs. GWC alone \[[@CR59]\], and promogran dressing plus GWC vs. GWC alone \[[@CR61]\]. Hyperbaric oxygen therapy plus usual care vs. usual care alone was found to be dominant in one study \[[@CR63]\], yet was more effective and more costly in another economic evaluation \[[@CR51]\].

Dominant interventions from studies scoring \<8 on the Drummond tool included hyperbaric oxygen therapy vs. control \[[@CR48]\], and hyperbaric oxygen therapy plus standard care vs. standard care alone \[[@CR63]\].

### Pressure ulcers {#Sec25}

Fourteen cost-effectiveness analyses evaluated pressure ulcer interventions (Table [10](#Tab10){ref-type="table"}) \[[@CR64]-[@CR77]\]. Ten studies found the interventions were dominant \[[@CR64],[@CR67],[@CR69],[@CR71]-[@CR77]\], and four of these were studies with a Drummond score ≥8 \[[@CR69],[@CR71],[@CR76],[@CR77]\]. These included moisture vapor permeable dressing vs. gauze \[for grade II pressure ulcers\] \[[@CR77]\], advanced dressings vs. simple dressings \[[@CR69]\], and hydrocolloid (DuoDERM) vs. gauze \[[@CR76]\]. Collagenase-containing ointment (Novuxol) vs. hydrocolloid (DuoDERM) dressing was found to be dominant in one study \[[@CR71]\], while collagen (Medifil) vs. hydrocolloid (DuoDERM) was more effective and more costly in another cost-effectiveness analysis \[[@CR70]\].

The following interventions were dominant in six studies with a Drummond score \<8: constant force technology mattress vs. low-air-loss mattress \[[@CR64]\], silver mesh dressing vs. silver sulfadiazine cream \[[@CR67]\], balsam Peru plus hydrogenated castor oil plus trypsin ointment vs. balsam Peru plus hydrogenated castor oil plus trypsin ointment plus other treatment (unspecified) for stage 1 and 2 wounds \[[@CR72]\], balsam Peru plus hydrogenated castor oil plus trypsin ointment plus other treatment (unspecified) vs. other treatment (unspecified) for stage 1 wounds \[[@CR72]\], balsam Peru plus hydrogenated castor oil plus trypsin ointment vs. other treatment (unspecified) for stage 2 wounds \[[@CR72]\], polyurethane foam dressing vs. saline gauze \[[@CR73]\], sequential granulocyte-macrophage/colony-stimulating factor and basic fibroblast growth factor vs. basic fibroblast growth factor alone \[[@CR74]\], sequential granulocyte-macrophage/colony-stimulating factor and basic fibroblast growth factor vs. granulocyte-macrophage/colony-stimulating factor alone \[[@CR74]\], and new hospital incentive system vs. non-introduced control \[[@CR75]\].

### Mixed wound types {#Sec26}

Three cost-effectiveness analyses evaluated mixed complex wound types (Table [11](#Tab11){ref-type="table"}) \[[@CR78]-[@CR80]\]. One study with a Drummond score ≥8 found that a multidisciplinary wound care team was dominant compared to usual care \[[@CR80]\].

Discussion {#Sec27}
==========

We conducted a comprehensive systematic review to summarize the cost-effectiveness of interventions for complex wound care including data from 59 cost-effectiveness analyses. These economic studies examined numerous interventions and comparators and used different outcomes to assess effectiveness. In a few situations, the intervention considered in one cost-effectiveness analysis comprised the comparator in another cost-effectiveness analysis. Therefore, cost-effectiveness results are presented as comparisons of one treatment option relative to another.

Based on evidence from 42 cost-effectiveness studies with a Drummond score ≥8, 22 intervention comparisons were dominant (Additional file [7](#MOESM7){ref-type="media"}). For venous ulcers, these were four-layer compression bandaging vs. usual care, skin replacement vs. Unna's Boot, Unna's boot vs. hydrocolloid, micronized purified flavonoid fraction plus usual care vs. usual care, durable barrier cream vs. no skin protectant, pentoxifylline plus compression vs. placebo plus compression, Manuka honey dressing vs. usual care, and amelogenin plus compression therapy vs. compression therapy only. For mixed venous and venous/arterial ulcers, only hydrocolloid dressing vs. saline gauze was dominant according to high quality cost-effectiveness analyses. For diabetic ulcers, cadexomer iodine ointment vs. usual care, filgrastim vs. placebo, intensified treatment vs. usual care, staged management diabetes foot program vs. usual care, ertapenem vs. piperacillin/tazobactam, ampicillin/sulbactam vs. imipenem/cilastatin, skin replacement plus GWC vs. GWC alone, promogran dressing plus GWC vs. GWC alone, and becaplermin gel (containing recombinant human platelet-derived growth factor) plus GWC vs. GWC alone were dominant. For pressure ulcers, moisture vapor permeable dressing vs. gauze, advanced dressings vs. simple dressings, and hydrocolloid vs. gauze were dominant. Finally, for mixed wound types, multidisciplinary wound care team was dominant vs. usual care.

Our results highlight a need for a future network meta-analysis given the numerous interventions and comparators available. Network meta-analysis is a statistical technique that can be used to combine direct evidence of effectiveness from head-to-head studies and indirect evidence of the relative benefits of interventions versus a common comparator (usually placebo). This powerful statistical approach can also be used to select the best treatment option available from a ranking of all treatments. An attractive property of network meta-analysis is that it allows researchers and health economists the opportunity to use the ranking analysis to generate a *de novo* cost-effectiveness analysis more efficiently. Another potential future study is to conduct a systematic review of clinical practice guidelines on complex wounds, and compare the interventions recommended in these with those found to be cost-effective in our review.

The major methodological quality limitation found in the included cost-effectiveness analyses was that the majority did not adequately establish the effectiveness of the wound care intervention using data from systematic reviews, randomized clinical trials, or observational studies that had sufficiently large sample sizes. Moreover, many of the included economic studies did not report on uncertainty of the cost-effectiveness estimates, incremental variabilities, or sensitivity analyses, thereby further limiting the utility of those results. Further, many of the cost-effectiveness analyses did not assess long-term cost-effectiveness, and the choice of timeframe for an economic evaluation might significantly affect the cost-effectiveness results. Given the chronic nature of many types of wounds, economic modeling of a longer time horizon would provide a clearer picture in many circumstances. As an example, an intervention might be more effective yet more costly in the first 2 months of usage but it might be cost saving over a 1 year or longer timeframe due to overall fewer additional interventions required. Furthermore, most of the cost-effectiveness studies did not include information on patient-reported quality of life, which is a major limitation of this literature.

The majority of the included economic studies were from European countries and 16 were from the United States. When trying to apply the cost-effectiveness results to a country-specific context, several factors need to be assessed such as the perspective of the economic evaluation (e.g., public payer, healthcare provider), the type of healthcare system (e.g., publicly-funded healthcare), the local practice of medicine, and local costs.

There are a few limitations related to our systematic review process worth noting. Due to resource constraints, we only included studies written in English. However, we contacted authors of non-English studies to obtain the English translations. In addition, although we contacted authors to share their unpublished data, only published literature was identified for inclusion. Finally, due to the numerous number of cost-effectiveness analyses included, we focused reporting on those with dominant results and a score ≥8 on the Drummond tool in the main text. We note that this is an arbitrary cut-off, and there is not an agreed upon method to provide a summary score on this tool. However, all of our results for all studies are presented in the tables and appendices despite dominance and score on the Drummond tool.

Conclusions {#Sec28}
===========

We conducted a comprehensive systematic review of cost-effectiveness studies for interventions to treat adult patients with complex wounds. Our results can be used by decision-makers to assist in maximizing the deployment of clinically effective and resource efficient wound care interventions. Our analysis also highlights specific treatments that are not cost-effective, thus indicating areas for potential improvements in efficiency. A network meta-analysis and *de novo* cost-effectiveness analysis will likely bring additional clarity to the field, as some of the findings were conflicting.

Additional files {#Sec29}
================

Additional file 1:**Wound care protocol.** Outlines the protocol used in the systematic review.Additional file 2:**MEDLINE search strategy.** Lists MEDLINE search terms.Additional file 3:**Classification of wound care interventions.** Lists the wound care interventions in each classification.Additional file 4:**Drummond's 10-item checklist tool used for cost-effectiveness analyses quality appraisal.** Provides the descriptions of the 10 items in Drummond's 10-item checklist tool.Additional file 5:**Cost-effectiveness analysis methodological quality appraisal results.** Lists the quality appraisal results for the 59 included cost-effectiveness analyses.Additional file 6:**Cost-effectiveness analyses sensitivity analysis, uncertainty of results and incremental variabilities.** Outlines the sensitivity analyses, level of uncertainty, and incremental variabilities for the cost-effectiveness analyses results.Additional file 7:**Summary of the less costly and more effective interventions for studies with a Drummond score ≥8.** Lists 42 cost-effectiveness studies with a Drummond score ≥8.

GWC

:   Good wound care

ICER

:   Incremental cost-effectiveness ratio

QALY

:   Quality-adjusted life-year

USD

:   United States dollar
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